Project Grant R21CA299578
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $637,473 on June 22, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on lineage plasticity in FGFR3-mutant bladder cancer and its role in therapeutic response. The research dissects three integrated aims: mechanistic understanding of how CDK8 and lineage-specifying transcription factors regulate lineage plasticity through genome-wide epigenetic and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $498,565 Project Grant to The University of Texas MD Anderson Cancer Center on September 8, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for locally advanced cervical cancer. The project, which extends through July 31, 2029, addresses a critical clinical need to risk-stratify cervical cancer patients undergoing...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $586,101 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in the bone tumor microenvironment of prostate cancer bone metastasis. The research addresses immune checkpoint therapy resistance in bone metastatic prostate cancer by characterizing how the bone tumor microenvironment conditions PMN-MDSCs to...
- The National Cancer Institute awarded Centro Comprensivo De Cancer De La Universidad De Puerto Rico $591,360 on August 27, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Type: Project Grant) to dissect the role of inherited non-coding variants in the enhancer architecture of breast cancer. The research investigates how inherited genetic variation alters enhancer function and transcriptional regulation in breast cancer, with specific focus on FOXA1, a...
- The National Cancer Institute awarded Texas A&M University System Health Science Center a $327,250 cooperative agreement on July 3, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify natural products targeting castration-resistant prostate cancer driven by androgen receptor splice variants, particularly AR-V7. During the UG3 phase, the recipient will miniaturize and transfer optimized phenotypic assays into a 1536-well format, establish robust cell-line...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $139,996 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support development of peptide-drug conjugates for the treatment of penile cancer. Work is performed in Houston, Texas, with a period of performance through July 31, 2028. The award is structured as a Project Grant, an assistance type within DHA's biomedical research portfolio that typically funds individual...
- The National Cancer Institute awarded $740,346 to The University of Texas MD Anderson Cancer Center on September 9, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393), a Project Grant classified as assistance funding. MD Anderson will develop efficient methods for measuring and characterizing genetic interactions in cancer cells using a CRISPR/Cas12a-based multiplexing system called IN4MER, which quantitates genetic interactions with five-fold fewer reagents than...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $717,715 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a multi-ancestry genome-wide association study of mammographic density phenotypes and their genetic and nongenetic determinants in over 120,000 multiethnic women. The project addresses the genetic basis of mammographic density—a strong and common breast cancer risk factor that reduces screening...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...